D.E. Shaw & Co
HUMA icon

D.E. Shaw & Co’s Humacyte HUMA Stock Holding History

D.E. Shaw & Co’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-158,584
Closed -$863K – 4584
2024
Q3 		$863K Sell
158,584
-427,378
-73% -$2.82M ﹤0.01% 3383
2024
Q2 		$2.81M Buy
585,962
+520,124
+790% +$2.71M ﹤0.01% 2320
2024
Q1 		$205K Buy
65,838
+43,298
+192% +$146K ﹤0.01% 3915
2023
Q4 		$64K Buy
+22,540
New +$57.9K ﹤0.01% 4008
2022
Q4 		– Sell
-31,776
Closed -$104K – 4963
2022
Q3 		$104K Sell
31,776
-20,565
-39% -$78.9K ﹤0.01% 4594
2022
Q2 		$168K Buy
52,341
+26,142
+100% +$145K ﹤0.01% 4602
2022
Q1 		$185K Buy
+26,199
New +$153K ﹤0.01% 4887

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's HUMA Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Humacyte (HUMA) in Q4 2024, closing a stake of 158,584 shares — an estimated $863K sold.

D.E. Shaw & Co first reported a position in HUMA in Q1 2022 and held it in 7 quarters. The position peaked at $2.81M in Q2 2024. 162 funds tracked by Wall St. Rank hold HUMA as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Humacyte position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 158,584 Humacyte shares in Q4 2024, an estimated $863K.
  • D.E. Shaw & Co first reported a position in Humacyte in Q1 2022 and held it in 7 quarters.
  • D.E. Shaw & Co's Humacyte position peaked at $2.81M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.